Hyperglycemia is a marker for poor clinical outcome and mortality in hospitalized patients. In the critical care setting, insulin administered intravenously or subcutaneously is effective.
SAN DIEGO — A single daily injection of fixed-dose insulin degludec/liraglutide (IDegLira) (Xultophy 100/3.6, Novo Nordisk) could offer an alternative to multiple daily insulin injections for patients ...
For patients with type 2 diabetes who are taking multiple daily insulin injections, switching to combination treatment with basal insulin plus an agent from one of two newer glucose-lowering drug ...
This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Diabetes, particularly type 2 diabetes (T2D), has become an epidemic in the United States, with a significant portion of patients unable to meet recommended glycemic targets. All individuals with type ...
BAGSVÆRD, Denmark, Sept. 17, 2019 /PRNewswire/ -- New data presented today at the 55 th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with ...
An AI tool showed noninferiority to senior endocrinology physicians in insulin titration for hospitalized patients with type 2 diabetes. About 99% of AI-based insulin recommendations were adopted by ...
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery - Observed weight loss was 17% at 28 days, a 25% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback